ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

AMGN Amgen Inc

284.79
-1.51 (-0.53%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 2,289,920
Bid Price 283.60
Ask Price 285.29
News -
Day High 288.565

Low
211.73

52 Week Range

High
329.72

Day Low 284.21
Company Name Stock Ticker Symbol Market Type
Amgen Inc AMGN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-1.51 -0.53% 284.79 20:00:00
Open Price Low Price High Price Close Price Prev Close
287.86 284.21 288.565 284.32 286.30
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
40,649 2,289,920 $ 285.69 $ 654,203,466 - 211.73 - 329.72
Last Trade Time Type Quantity Stock Price Currency
19:28:09 24 $ 284.78 USD

Amgen (AMGN) Options Flow Summary

Overall Flow

Bullish

Net Premium

372k

Calls / Puts

255.56%

Buys / Sells

400.00%

OTM / ITM

45.45%

Sweeps Ratio

0.00%

Amgen Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
152.37B 535.92M - 28.19B 6.72B 12.53 22.68
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Amgen News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No AMGN Message Board. Create One! See More Posts on AMGN Message Board See More Message Board Posts

Historical AMGN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week274.85288.565274.39280.462,669,1609.943.62%
1 Month278.52288.565268.17275.113,139,8566.272.25%
3 Months301.50329.72268.17291.713,054,645-16.71-5.54%
6 Months267.79329.72249.7001282.772,757,38417.006.35%
1 Year237.00329.72211.73262.422,589,37647.7920.16%
3 Years251.53329.72198.64246.652,720,92933.2613.22%
5 Years187.08329.72165.06235.132,703,57197.7152.23%

Amgen Description

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Your Recent History

Delayed Upgrade Clock